Press release content from PR Newswire. The AP news staff was not involved in its creation.
BEIJING and BOSTON, Sept. 24, 2020 /PRNewswire/ — In August, Beijing Biocytogen Biotechnology Co., Ltd. (“Biocytogen”) announced acquisition of Eucure Biopharma, which established Biocytogen as a clinical stage company. Now, Biocytogen is pleased to announce completion of series D1 Funding, successfully raising 142 million dollars (USD) meant to further secure the implementation of Project Integrum.
Project Integrum is a humanitarian effort to discover, develop, and bring to market novel therapeutic antibody candidates against all notoriously difficult druggable targets. Taking full advantage of Biocytogen’s integrated technology platforms for antibody discovery, Project Integrum will launch pre-clinical efforts into over 1,000 human diseases currently affecting countless lives.
Meticulous screening of antibody candidates both in vivo and in vitro improves clinical translatability dramatically. At the core of Biocytogen lie the humanized antibody RenMab Mouse